J&J Licenses Amgen Neuropathic Pain Candidate AMG 403
This article was originally published in The Pink Sheet Daily
Executive Summary
Realities of today’s biopharma business push former foes to shake hands once again.
You may also be interested in...
Safety Of Anti-NGFs For Osteoarthritis Pain To Be Weighed By Advisory Panel
The entire class of biologics has fallen under suspicion of worsening the very condition it is supposed to treat, and FDA has imposed clinical holds on ongoing trials.
Safety Of Anti-NGFs For Osteoarthritis Pain To Be Weighed By Advisory Panel
The entire class of biologics has fallen under suspicion of worsening the very condition it is supposed to treat, and FDA has imposed clinical holds on ongoing trials.
Amgen Shortens Epogen, Procrit Shelf-lives Following Recall
Firm is working with vial manufacturers to determine the cause of the delamination.